Observational studyDiabetes, obesity & metabolism2025
Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.
Observational study in Diabetes, obesity & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Peer Referral Pathways and 6-Month Outcomes in a Tirzepatide-Supported Digital Weight Loss Service: Retrospective Cohort Study.Journal of medical Internet research · 2026Article
- Employee perceptions and experiences with tirzepatide treatment for obesity or overweight in the US: Insights from the PERCEPTIONS Survey.Obesity pillars · 2026Article
- Digital Engagement Phenotypes and 6-Month Weight Loss in a Tirzepatide-Supported Digital Weight-Loss Program: A Retrospective Cohort Study.Medicina (Kaunas, Lithuania) · 2026Article
- Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.Diabetes, obesity & metabolism · 2026Review
- Multi-target-directed drugs: new additions in 2025 and post-marketing safety surveillance of drugs marketed in 2022-2024.Pharmacological reports : PR · 2026Review
- Case report: Tirzepatide-associated morbilliform drug eruption and implications for rising glucagon-like peptide-1 agonist use.JAAD case reports · 2026Article
- Review
- Article
- Persistence-Dependent Effectiveness of Tirzepatide on the Cardio-Metabolic-Kidney Syndrome Outcomes in Obesity: Real-World Evidence from the United Arab Emirates.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2026Article
- Clinical characteristics, treatment patterns, and healthcare utilization among children, adolescents, and young adults with obesity in the United States.Obesity pillars · 2026Article
- Use of Semaglutide and Tirzepatide in Rheumatic and Musculoskeletal Diseases: Insights on Initiation Patterns and Weight Loss From the Rheumatology Informatics System for Effectiveness Registry.ACR open rheumatology · 2026Article
- Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity.BMJ open diabetes research & care · 2026Review
- Mapping the global research landscape of tirzepatide: a bibliometric analysis of trends, collaborations, and emerging themes in obesity and diabetes managements.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Recent Studies on the Effectiveness and Safety of Anti-Obesity Medications: A Scoping Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
- Real-world effects of incretin-based Obesity medications on body composition.Obesity pillars · 2025Article
- Real-World Effectiveness of Tirzepatide versus Semaglutide on HbA1c and Weight in Patients with Type 2 Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025Article
- Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE).Advances in therapy · 2025Article
- Real-world titration, persistence & weight loss of semaglutide and tirzepatide in an academic obesity clinic.Diabetes, obesity & metabolism · 2025Article
- Real-world use and effectiveness of tirzepatide among individuals without type 2 diabetes: Results from the Optum Market Clarity database.Diabetes, obesity & metabolism · 2025Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsTo understand real-world tirzepatide utilization and effectiveness (change in weight and body mass index [BMI]) among people without type 2 diabetes (T2D) in the United States. MATERIALS AND
methodsThis retrospective, observational study used Optum's de-identified Market Clarity database (index date: first-observed tirzepatide claim; index period: 13 May 2022-30 September 2023). Outcomes were assessed in 3 cohorts: (1) Overall cohort: age ≥18 years; ≥1 tirzepatide claim; no baseline T2D diagnosis codes, anti-diabetes medication use (except metformin) or glycated haemoglobin ≥6.5%; continuous medical and pharmacy enrolment for ≥12 months pre-index. (2) Utilization cohort: all above criteria and anti-obesity medication (AOM)-eligible individuals (BMI ≥30 kg/m
resultsOverall cohort included 20,998 individuals (mean age: 47.4 years, female: 74.9%, mean BMI: 36.9 kg/m
conclusionsReal-world evidence suggests multimorbidity is common among tirzepatide initiators. While tirzepatide dose escalation was slower than in clinical trials, individuals achieved weight reduction at 6 months, consistent with clinical trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.